<DOC>
	<DOCNO>NCT00965094</DOCNO>
	<brief_summary>The primary objective trial show non-inferiority CNI-free regimen respect renal function Month 9 post Tx assess glomerular filtration rate - Nankivell method - compare standard CNI-based regimen de novo renal transplant patient .</brief_summary>
	<brief_title>Efficacy Safety Everolimus+EC-MPS After Early CNI Elimination v EC-MPS +Tacrolimus Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<criteria>Inclusion criterion : Recipients de novo cadaveric , live unrelated living relate kidney transplant Females capable become pregnant must negative serum pregnancy test within 7 day prior screen , required practice approve method birth control duration study period 6 week follow discontinuation study medication , even history infertility . Patients willing able participate study write informed consent obtain . Exclusion criterion : More one previous renal transplantation Multiorgan recipient ( e.g. , kidney pancreas ) previous transplant organ , different kidney Donor age : &lt; 5 year &gt; 65 year Graft loss due immunological reason first year transplantation ( case secondary transplantation ) Patients receive investigational drug within 4 week baseline period Patients recipient ABO incompatible transplant T cell crossmatch positive transplant Patients already exist antibody HLAtype receive transplant Patients know hypersensitivity Simulect® , Certican® , mycophenolic acid , Prograf® , drug similar Certican® ( e.g. , macrolides ) , component formulation . Patients receive investigational immunosuppressive drug within four week prior study entry ( Baseline visit 1 ) Patients thrombocytopenia ( platelet &lt; 75,000/mm³ ) , absolute neutrophil count &lt; 1,500/mm³ leucopenia ( leucocytes &lt; 2,500/mm³ ) , hemoglobin &lt; 6 g/dL Patients preexist lung disease ( alveolitis , fibrosis ) Patients symptoms significant somatic mental illness . Inability cooperate communicate investigator , unlikely comply study requirement , unable give inform consent Patients history malignancy last five year , except squamous basal cell carcinoma skin Patients HIV positive Hepatitis B surface antigen positive Hepatitis C virus positive . Recipients organs donor test positive Hepatitis B surface antigen Hepatitis C exclude . Evidence severe liver disease ( incl . abnormal liver enzyme profile , i.e . AST , ALT total bilirubin &gt; 3 time UNL ) Females childbearing potential planning become pregnant , pregnant lactating , and/or unwilling use effective mean contraception ( see also section 8.2 ) Presence clinically significant infection require continued therapy , severe diarrhea , active peptic ulcer disease , uncontrolled diabetes mellitus opinion investigator would interfere appropriate conduct study Evidence drug alcohol abuse Patients receive drug know interact Tacrolimus and/or everolimus accord list provide Appendix 3 protocol . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>